SOP for clinical trial safety reporting – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Mon, 27 Oct 2025 23:23:18 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 SOP for Selective Safety Data Collection (ICH E19) https://www.clinicalstudies.in/sop-for-selective-safety-data-collection-ich-e19/ Mon, 27 Oct 2025 23:23:18 +0000 ]]> https://www.clinicalstudies.in/?p=7098 Read More “SOP for Selective Safety Data Collection (ICH E19)” »

]]>
SOP for Selective Safety Data Collection (ICH E19)

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-selective-safety-data-collection-ich-e19”
},
“headline”: “SOP for Selective Safety Data Collection (ICH E19)”,
“description”: “This SOP outlines standardized procedures for implementing selective safety data collection in clinical trials in compliance with ICH E19. It defines strategies for optimizing safety data collection while maintaining participant safety and regulatory compliance.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Selective Safety Data Collection (ICH E19)

SOP No. CR/OPS/158/2025
Supersedes NA
Page No. X of Y
Issue Date 26/08/2025
Effective Date 01/09/2025
Review Date 01/09/2026

Purpose

The purpose of this SOP is to establish processes for selective safety data collection in clinical trials, in alignment with ICH E19. This approach ensures optimization of safety data collection where comprehensive data are not required, while maintaining subject protection, regulatory compliance, and integrity of safety evaluation.

Scope

This SOP applies to sponsors, CROs, investigators, and pharmacovigilance (PV) teams involved in safety data management in clinical trials. It covers identification of trials eligible for selective data collection, definition of selective data parameters, documentation, and reporting procedures.

Responsibilities

  • Sponsor: Defines rationale for selective safety data collection and ensures regulatory approval.
  • CRO: Implements selective data collection procedures across sites.
  • Investigator: Collects and documents only the predefined safety data points.
  • PV Department: Ensures selective data is analyzed and reported appropriately.
  • QA: Audits selective safety data processes for compliance with ICH E19.

Accountability

The Sponsor’s Pharmacovigilance Head is accountable for ensuring selective safety data collection aligns with ICH E19 guidance and does not compromise patient safety or trial integrity.

Procedure

1. Identification of Eligible Trials
1.1 Determine trial types suitable for selective safety data collection (e.g., late-phase or pragmatic trials).
1.2 Justify the rationale in trial protocols.
1.3 Document in Trial Eligibility Log (Annexure-1).

2. Defining Selective Safety Parameters
2.1 Define which safety data (AEs, SAEs, concomitant medications) will be collected.
2.2 Obtain regulatory and EC approval.
2.3 Record in Safety Parameters Log (Annexure-2).

3. Investigator Training
3.1 Train investigators and staff on selective safety data collection.
3.2 Document training in Investigator Training Log (Annexure-3).

4. Data Collection and Reporting
4.1 Collect only predefined safety data at site level.
4.2 Record in Selective Safety Data Collection Log (Annexure-4).
4.3 Report aggregated data to sponsor and regulators.

5. Analysis and Oversight
5.1 Analyze collected data for trends and risk signals.
5.2 Escalate unexpected safety concerns to regulators.
5.3 Document in Oversight Log (Annexure-5).

6. Archiving
6.1 Archive selective safety data and related approvals in TMF.
6.2 Record in Safety Archiving Log (Annexure-6).

Abbreviations

  • SOP: Standard Operating Procedure
  • PV: Pharmacovigilance
  • ICH: International Council for Harmonisation
  • AE: Adverse Event
  • SAE: Serious Adverse Event
  • CRO: Contract Research Organization
  • QA: Quality Assurance
  • TMF: Trial Master File
  • EC: Ethics Committee

Documents

  1. Trial Eligibility Log (Annexure-1)
  2. Safety Parameters Log (Annexure-2)
  3. Investigator Training Log (Annexure-3)
  4. Selective Safety Data Collection Log (Annexure-4)
  5. Oversight Log (Annexure-5)
  6. Safety Archiving Log (Annexure-6)

References

Version: 1.0

Approval Section

Prepared By Ravi Kumar, PV Specialist
Checked By Sunita Reddy, QA Officer
Approved By Dr. Anil Sharma, Head Pharmacovigilance

Annexures

Annexure-1: Trial Eligibility Log

Date Protocol ID Eligibility Assessment Prepared By Status
01/09/2025 SEL-2025-01 Eligible for Selective Collection Reg Affairs Approved

Annexure-2: Safety Parameters Log

Date Parameter Decision Authority Status
02/09/2025 Concomitant Medications Only EC Approved

Annexure-3: Investigator Training Log

Date Investigator Training Topic Trainer Status
03/09/2025 Dr. Meera Joshi Selective Safety Data Collection QA Officer Completed

Annexure-4: Selective Safety Data Collection Log

Date Subject ID Parameter Collected Collected By Status
05/09/2025 SUB-601 Concomitant Medications Investigator Recorded

Annexure-5: Oversight Log

Date Oversight Activity Performed By Status
07/09/2025 Trend Analysis PV Specialist Completed

Annexure-6: Safety Archiving Log

Date Document Archived By Location Status
10/09/2025 Selective Safety Data Logs QA TMF Archived

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
26/08/2025 00 Initial version New SOP creation Head Pharmacovigilance

For more SOPs visit: Pharma SOP

]]>